Dr. Friedman on the Future of Selinexor in Multiple Myeloma

Robb S. Friedman, MD, a hematologist and oncologist at Massachusetts General Hospital, discusses the future of selinexor (Xpovio) in multiple myeloma.
Website: https://www.onclive.com
Twitter: https://twitter.com/OncLive
Facebook: https://www.facebook.com/OncLive/
LinkedIn: https://www.linkedin.com/company/onclive